We work with a leading, global pharmaceutical company
We work with industry leader, Allergan, in the field of ophthalmology, to leverage the full potential and reach of our multi-DARPin® platform. This collaboration is designed to speed the discovery and development of breakthrough therapies, creating value for both partners and ultimately bringing improved health outcomes to patients with serious diseases.
How We Partner
Molecular Partners’ strategy is to maximize the potential of its multi-DARPin® platform through in-house development, collaborations and licensing. Our partnerships with Allergan has the potential for CHF 1.7 billion in milestone payments and up to double-digit royalties on all licensed products.
In 2011, the Company licensed its lead asset MP0112, now called abicipar, to Allergan. In 2012, Molecular Partners and Allergan expanded their relationship by signing two separate new agreements to discover, develop, and commercialize proprietary therapeutic DARPin® products for the treatment of serious ophthalmic diseases. The Company received combined upfront payments of $107.5 million under the three agreements and is eligible to potentially receive additional success-based payments, including up to $1.7 billion in aggregate development, regulatory and sales milestones, and tiered royalties for future product sales.
DARPin® is a registered trademark owned by Molecular Partners AG.